136 citations
,
April 2013 in “Clinical Cancer Research” The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.
127 citations
,
August 2016 in “The oncologist” This paper reviews adverse events related to hedgehog pathway inhibitors in advanced basal cell carcinoma patients, reporting no new clinical results but aiming to inform healthcare professionals for improved patient care.
21 citations
,
November 2021 in “Cells” This review discusses the challenges and opportunities in targeting the hedgehog pathway for aggressive cancers, emphasizing the complexities of treatment resistance, immune response, and the potential of combining immune checkpoint inhibitors with hedgehog pathway inhibitors, but reports no new clinical results.
10 citations
,
June 2024 in “American Journal of Clinical Dermatology” This review highlights that while sonidegib and vismodegib offer promising treatment options for advanced basal cell carcinoma, their use is often limited by treatment-emergent adverse events, which can be managed through protocol modifications and supportive interventions.
January 2026 in “International Journal of Molecular Sciences” This study found that inhibiting the Hedgehog pathway may reduce proliferation and migration in melanoma, suggesting its potential repurposing as a therapeutic target.